ArticleFrontiers in oncology2022

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.

Rossella Iula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.